Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary clinical objective is to determine the efficacy of a standard 1st line regimen (FOLFOX and cetuximab) in patients with RAS/BRAF wildtype, MSI or MSS MCRC with avelumab in terms of progression free survival rate after 12 months (acc. to RECIST v1.1).
Critère d'inclusion
- Metastatic colorectal cancer